“Palm reading”: 2. Handheld software for physicians

od Adatia, Feisal, Bedard, Philippe L.
Izdano 2003

Luminal-B breast cancer and novel therapeutic targets

od Tran, Ben, Bedard, Philippe L
Izdano 2011

Decoding the evolution of a breast cancer genome

od Bedard, Philippe L, Sotiriou, Christos
Izdano 2010

“Palm reading”: 1. Handheld hardware and operating systems

od Adatia, Feisal A., Bedard, Philippe L.
Izdano 2002

The perils of PDAs

od Adatia, Feisal A., Bedard, Philippe L.
Izdano 2003

Salvage chemotherapy for metastatic germ cell tumours: The known unknowns

od Hansen, Aaron R., Bedard, Philippe L.
Izdano 2012

Clinical application of high-throughput genomic technologies for treatment selection in breast cancer

od Hansen, Aaron R, Bedard, Philippe L
Izdano 2013

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

od Snoj, Natasa, Bedard, Philippe L, de Azambuja, Evandro, Cardoso, Fatima, Piccart, Martine
Izdano 2009

Tumour heterogeneity in the clinic

od Bedard, Philippe L., Hansen, Aaron R., Ratain, Mark J., Siu, Lillian L.
Izdano u Nature (2013)

The Future of Clinical Trials Design in Oncology

od Spreafico, Anna, Hansen, Aaron R., Abdul Razak, Albiruni R., Bedard, Philippe L., Siu, Lillian L.
Izdano u Cancer Discov (2021)

Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer

od Aung, Kyaw L., Stockley, Tracy L., Serra, Stefano, Kamel-Reid, Suzanne, Bedard, Philippe L., Siu, Lillian L.
Izdano u Cold Spring Harb Mol Case Stud (2016)

Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy

od Calleja, Anna, Poulin, Frédéric, Khorolsky, Ciril, Shariat, Masoud, Bedard, Philippe L., Amir, Eitan, Rakowski, Harry, McDonald, Michael, Delgado, Diego, Thavendiranathan, Paaladinesh
Izdano u J Oncol (2015)

Feasibility Assessment of Using the Complete Patient‐Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO‐CTCAE) Item Library

od Shepshelovich, Daniel, McDonald, Kate, Spreafico, Anna, Razak, Albiruni R.A., Bedard, Philippe L., Siu, Lillian L., Minasian, Lori, Hansen, Aaron R.
Izdano u Oncologist (2019)

Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era

od Tan, Tira, Rheaume, Michael, Wang, Lisa, Chow, Helen, Spreafico, Anna, Hansen, Aaron R., Razak, Albiruni R.A., Siu, Lillian L., Bedard, Philippe L.
Izdano u Oncologist (2019)

International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy

od Cardoso, Fatima, Bedard, Philippe L., Winer, Eric P., Pagani, Olivia, Senkus-Konefka, Elzbieta, Fallowfield, Lesley J., Kyriakides, Stella, Costa, Alberto, Cufer, Tanja, Albain, Kathy S.
Izdano 2009

The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours

od Nayan, Madhur, Jewett, Michael A.S., Anson-Cartwright, Lynn, Bedard, Philippe L., Moore, Malcolm, Chung, Peter, Warde, Padraig, Sweet, Joan, O’Malley, Martin, Hamilton, Robert J.
Izdano u Can Urol Assoc J (2016)

Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy

od Cunningham, Morven, Iafolla, Marco, Kanjanapan, Yada, Cerocchi, Orlando, Butler, Marcus, Siu, Lillian L., Bedard, Philippe L., Ross, Kendra, Hansen, Bettina, Spreafico, Anna, Feld, Jordan J.
Izdano u PLoS One (2021)

A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors

od McDonald, Paul C., Chia, Stephen, Bedard, Philippe L., Chu, Quincy, Lyle, Michael, Tang, Liren, Singh, Madhu, Zhang, Zaihui, Supuran, Claudiu T., Renouf, Daniel J., Dedhar, Shoukat
Izdano u Am J Clin Oncol (2020)

Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?

od Hatzis, Christos, Bedard, Philippe L., Juul Birkbak, Nicolai, Beck, Andrew H., Aerts, Hugo J. W. L., Stern, David F., Shi, Leming, Clarke, Robert, Quackenbush, John, Haibe-Kains, Benjamin
Izdano 2014

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

od Harding, James J., Bauer, Todd M., Tan, Daniel S. W., Bedard, Philippe L., Rodon, Jordi, Doi, Toshihiko, Schnell, Christian, Iyer, Varsha, Baffert, Fabienne, Radhakrishnan, Rajkumar, Fabre, Claire, Juric, Dejan
Izdano u Invest New Drugs (2018)